Menu

Insights

Home » Insights » Insights Intercept Blood System
Transfusion-Transmitted Infections 07/01/2019

INTERCEPT Blood System supports blood supply during West Nile virus epidemic in France

Since the beginning of July 2018, the Mediterranean region has experienced an epidemic of West Nile virus infections: 24 cases in three French regions (Paca, Corsica and Occitania), according to the latest report from Public Health France. The disease is transmitted by the Culex mosquito.

Transfusion-Transmitted Infections 06/11/2018

Platelet transfusion-associated bacterial sepsis cases reported in Utah and California

The US Department of Health and Human Services, Centers for Disease Control (CDC) recently published details related to fatal sepsis cases that resulted from bacterially contaminated conventional platelet components.
Regulations 08/08/2018

Pathogen Inactivation, towards becoming the standard of care in Germany

As of January 1, 2018, specific reimbursement for pathogen inactivated platelets is now available in Germany.

Cerus 08/08/2018

Madrid adopts INTERCEPT

On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPTTM Blood System for platelets.

Cerus 08/08/2018

EFS adopts INTERCEPT

The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).

Cerus 06/08/2018

Let us do something about it!

In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.